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Background: Vpu is a multifunctional accessory protein that enhances the release of HIV-1 by counteracting the
entrapment of nascent virions on infected cell surface mediated by BST2/Tetherin. Vpu-mediated BST2 antagonism
involves physical association with BST2 and subsequent mislocalization of the restriction factor to intracellular
compartments followed by SCF(β-TrCP) E3 ligase-dependent lysosomal degradation. Apart from BST2 antagonism,
Vpu also induces down regulation of several immune molecules, including CD4 and SLAMF6/NTB-A, to evade host
immune responses and promote viral dissemination. However, it should be noted that the multiple functions of
Vpu have been studied in cell-based assays, and thus it remains unclear how Vpu influences the dynamic of HIV-1
infection in in vivo conditions.
Results: Using a humanized mouse model of acute infection as well as CCR5-tropic HIV-1 that lack Vpu or encode
WT Vpu or Vpu with mutations in the β-TrCP binding domain, we provide evidence that Vpu-mediated BST2
antagonism plays a crucial role in establishing early plasma viremia and viral dissemination. Interestingly, we also
find that efficient HIV-1 release and dissemination are directly related to functional strength of Vpu in antagonizing
BST2. Thus, reduced antagonism of BST2 due to β-TrCP binding domain mutations results in decreased plasma
viremia and frequency of infected T cells, highlighting the importance of Vpu-mediated β-TrCP-dependent BST-2
degradation for optimal initial viral propagation.
Conclusions: Overall, our findings suggest that BST2 antagonism by Vpu is critical for efficient early viral expansion
and dissemination during acute infection and as such is likely to confer HIV-1 increased transmission fitness.
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Studies over the last decade have provided ample evi-
dence to suggest that host cells deploy multiple mecha-
nisms to counter human immunodeficiency virus (HIV)
infection. These intrinsic/innate antiviral host cell re-
sponses are mediated by an array of host restriction
factors such as APOBEC3F/G, SamHD1, and BST2 (also
called Tetherin, CD317, HM1.24). However, HIV has
evolved to encode accessory proteins such as Vif, Vpx
and Vpu to antagonize these host restriction factors,
thus permitting efficient viral replication and evasion of
innate immune responses [1,2]. One extensively studied* Correspondence: eric.cohen@ircm.qc.ca
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reproduction in any medium, provided the orhost restriction factor is BST2, a protein that is broadly in-
duced by type 1 interferon (IFN) in various cell types,
including CD4+ T cells and macrophages, suggesting im-
portant roles for this factor in antiviral innate responses
[3-5]. BST2 is a type II membrane protein that contains
two membrane anchors imparting a unique topology to
the protein. It consists of a short N-terminal cytosolic tail,
a transmembrane domain (TMD), an extracellular portion
that is predominantly helical and a glycophosphatidyl-
inositol (GPI)-linked membrane anchor present at the C-
terminus. This distinctive configuration permits BST2 to
insert one membrane anchor into budding HIV-1 particles
and thus inhibit the release of virions through tethering of
nascent viral particles to the plasma membrane (PM)
[4-7]. While it is generally agreed that BST2 impairs the
release of cell-free HIV-1 particles, it is a subject of debate
whether the BST2 mediated restriction affects viral cell-
to-cell transmission, the most efficient mode of HIV-1d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for BST2 or encoding single nucleotide polymorphism in
BST2 have underlined the importance of this effector of
the IFN antiviral response in restricting retrovirus replica-
tion and disease progression in vivo [10,11].
To counter the ability of BST2 to inhibit virus release
from infected cells, HIV-1 encodes Vpu, which was the
first BST2 antagonist to be identified [4,5]. Vpu is a type I
membrane protein containing a TMD and a carboxy-
terminal cytoplasmic tail domain (CTD). The past few
years have seen extensive characterization of Vpu-BST2 in-
teractions and these studies have shown that the TMD of
Vpu and BST2 are crucial for direct physical interactions
between the two proteins and indeed govern the species
specific basis of BST2 antagonism [12-14]. Importantly,
Vpu interaction with BST2 results in mislocalization of the
restriction factor from the PM to endosomal and peri-
nuclear compartments, namely the TGN, thus leading to
an overall reduction of BST2 levels at the cell surface
[15-18]. Thus, mutating Vpu at specific positions in the
TMD resulted in failure to down regulate BST2 from the
cell surface and inefficient HIV-1 release [12,14].
Apart from the TMD, the CTD of Vpu is also involved
in BST2 antagonism. This region of Vpu consists of two
alpha helices separated by a hinge region containing two
phosphorylatable serine residues, S52 and S56, that are
required to recruit β-TrCP, a substrate recognition mod-
ule of the Skp1/Cullin/Fbox (SCFβ-TrCP) E3 ubiquitin
ligase complex [19]. Increasing evidence suggests that
SCFβ-TrCP-dependent ubiquitination of the restriction
factor contributes to BST2 antagonism by targeting cell
surface BST2 as well as de novo synthesized BST2 for
degradation in the lysosomes [15,20-23]. It should be
noted that preventing Vpu-mediated β-TrCP dependent
degradation of BST2 does not completely abolish BST2
antagonism in several cellular models [16,17,24-27], in-
dicating that Vpu can inhibit BST2 function independ-
ently of degradation. Similarly, putative sorting motifs
present in the CTD of Vpu also play critical roles in tar-
geting BST2-Vpu complex to intracellular compartments
where BST2 is precluded from the area of viral assembly
at PM [25,28].
Vpu also performs several other functions with implica-
tions for immune response as well as viral release and
infectivity. Thus, Vpu induces the ubiquitination and pro-
teasomal degradation of newly synthesized CD4 molecules
that form a complex with the envelop precursor gp160
(Env) in the endoplasmic reticulum (ER) via a mechanism
that strictly depends on β-TrCP recruitment [19,29-31]. It
should be noted that HIV-1 down regulates and degrades
CD4 not only through Vpu, but also in concert with Env
and Nef viral proteins. Although the biological relevance
of HIV-1-mediated CD4 down regulation is still unclear,
it could enhance viral infectivity by alleviating CD4sequestration of Env, a condition that impedes efficient
trafficking of Env towards viral assembly sites at the PM,
and/or prevent superinfection [32-34]. Recent data also
suggest that Vpu down regulates cell-surface immune
molecules such as the co-activating NK receptor NK,
T-cell, B cell antigen (NTB-A) (also termed CD352 or
SLAMF6) [35] as well as, to a lesser extent, PVR (also
termed CD155 or Necl-5), the ligand of the activating NK
cell receptor DNAM-1 [36], to evade recognition and kill-
ing of infected T cells by NK cells.
The aforementioned multiple functions of Vpu have
been largely studied employing permissive and non per-
missive cell lines or primary HIV target cells such as
CD4+ T cells and macrophages. However, recent techno-
logical advances have made it possible to employ hu-
manized mouse (hu-mice) model for studies of HIV-1
infection under in vivo conditions. Indeed, a recent
study demonstrated that hu-mice infected with Vpu-
sufficient but not -deficient HIV-1 exhibited an initial
burst phase of viral propagation that correlated with a
down regulation of BST2 and CD4 in infected CD4+ T
cells [37]. However, the consequence of Vpu-mediated
target protein trafficking alteration and/or degradation
under in vivo condition remains to be dissected. For
instance, it is not clear if impairing Vpu-mediated ubi-
quitination and degradation of BST2 and CD4 (via re-
cruitment of β-TrCP) has the same effect on HIV-1
replication and dissemination.
In this study, we used the humanized NOD-scid
IL2Rγnull (NSG) mouse model of acute HIV infection as
well as CCR5-tropic HIV-1 virus that lack Vpu or en-
code WT Vpu or Vpu with mutations in the β-TrCP-
binding site to assess the role of Vpu-mediated BST2
antagonism in establishing efficient plasma viremia and
viral dissemination in lymphoid tissues during infection
in vivo.
Results
Impact of Vpu-deficiency on HIV-1 replication and propa-
gation in hu-mice
A group of NSG mice reconstituted with human cord-
blood-derived CD34+ stem cells (hu-mice) were infected
with CCR5-tropic HIV-1 (pNL4.3-Ada-GFP) expressing
Vpu (HIV-1-WT) or lacking Vpu (HIV-1-ΔVpu). It is im-
portant to note that the Vpu protein encoded by pNL4.3-
Ada-GFP originates from the Ada strain and not the
prototypical pNL4.3 variants. Transfection of HeLa cells
with WT and ΔVpu proviral DNA revealed that WT HIV-
1 down regulated endogenously expressed surface BST2 in
a Vpu-dependent manner and that reduction of BST-2
levels at the surface of HIV-1 producing cells correlated
with efficient virus particle release (Figure 1A-C). Further-
more, infection of activated primary human CD4+ T






















































































































































































Figure 1 Characterization of CCR5-tropic HIV-1-WT and HIV-1-ΔVpu proviral DNA and viruses. HeLa cells were transfected with WT or Vpu-
deficient pNL4.3-Ada-GFP proviral DNA. Transfected cells and virus-containing supernatants were analyzed by western blot using the indicated
antibodies (A). Relative virus particle release efficiency. The particle release efficiency of HIV-1-WT was set at 100% (average of 3 independent
experiments) (B). An aliquot of transfected cells was used for analysis of BST2 levels at the surface of GFP-positive (HIV-expressing cells; dashed
line) and -negative (non-transfected cells; continuous line) cells by flow cytometry (representative of n = 3). Gray filled histogram represents
preimmune staining with normal rabbit serum (C). Primary CD4+ T cells were isolated from healthy donors and activated with PHA and IL-2.
Activated T cells were infected with HIV-1-WT or HIV-1-ΔVpu at an MOI of 1. At different time points post infection, an aliquot of culture was
collected for flow cytometry analysis of CD4 and BST2 expression at the surface of GFP-positive (infected; dashed line) or -negative (non infected;
continuous line) cells. Data is shown for cells collected 3 days post infection (dpi). Relative BST2 and CD4 levels at 3-dpi on p24- (open bar) and
p24+ (filled bar) cells are shown (MFI on p24-negative = 100%; n = 2, * p≤ 0.05, N.S.: not significant). (D). Infectious virus production in supernatant
was determined by assessing the levels of luciferase activity (in duplicate) following infection of HeLaTZM-bl reporter cells (E). Data are representative
of 3 independent experiments. Error bars represent standard deviations (SD).
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Lastly, both viruses had the ability to down regulate the
CD4 receptor at the cell surface with what appeared a
minor but reproducible contribution resulting from Vpu
(Figure 1D-E). However, statistical significance could not
be achieved.
To determine the impact of Vpu on viral replication
and propagation under in vivo conditions, we initially in-
fected hu-mice with low dose (~5,000 TCID50) of HIV-
1-WT or HIV-1-ΔVpu virus. Hu-mice were bled every
alternate week for up to 18 weeks post infection (wpi)
for estimation of viral load in plasma and frequency of
CD4+ T cells in the blood. As shown in Figure 2A, HIV-
1-WT-infected hu-mice showed detectable levels of
plasma viral load as early as 2-wpi and it increased fur-
ther at 4-wpi, a level that was maintained up to 18-wpi.
In contrast, HIV-1-ΔVpu infected hu-mice showed de-
layed and reduced plasma viral load kinetics especially at
early time points (2–6 wpi) with peak viral load achieved
only between 12- and 16-wpi. Thus at 4- and 18-wpi
average plasma viral load in HIV-1-WT infected hu-
mice was ~150- and ~5-fold more compared to HIV-1-
ΔVpu infected animals. Interestingly, the differences in
absolute plasma viremia between the two groups of hu-
mice became less significant 14-wpi onwards, indicating
that over time HIV-1-ΔVpu replication could reach
levels similar to those of HIV-1-WT and suggesting that
HIV-1 -ΔVpu virus are ultimately able to overcome
host cell restrictions. Analysis of peripheral blood T cells
showed that the average frequency of p24+ T cells in
blood from HIV-1-WT infected hu-mice was higher
than that from their HIV-1-ΔVpu infected counterparts
especially at early time points (4-8wpi); however, statis-
tical significance could not be achieved due to large vari-
ations in frequency of p24+ T cells in individual hu-mice
(Additional file 1: Figure S1A). Detection of infected
cells by measurement of virus-encoded GFP could not
be used as a substitute as it was less sensitive compared
to Gag staining. Moreover, a decrease in CD4+ T cell fre-
quency in blood was observed at 12-wpi and later time
points in HIV-1-WT infected hu-mice compared to
HIV-1-ΔVpu infected hu-mice (Additional file 1: Figure
S1B). This fastest rate of CD4+ T cell depletion by HIV-1
WT virus most probably reflects the more rapid infec-
tion dynamic of these viruses relative to their ΔVpu
counterparts.
To study the effect of Vpu on viral dissemination and
to determine whether Vpu deficiency affected BST2 and
CD4 expression on infected T cells in vivo, we sacrificed
hu-mice at 8 to 10-wpi for analysis of splenic cells by
flow cytometry. Figure 2B and 2C show analysis and fre-
quency of infected (p24+) T cells in the CD3+CD8-
splenic subset of hu-mice infected with WT or Vpu-
deficient HIV-1. It should be noted that more than 90%of CD3+CD8- cells belong to the CD4 lineage (see top
panel in second column of Figure 2C). Spleen of hu-
mice infected with HIV-1-WT contained ~ three times
more p24+ cells than those of hu-mice infected with
HIV-1-ΔVpu, indicating that WT virus disseminated
more efficiently to lymphoid tissues than HIV-1-ΔVpu
(Figure 2B). Flow cytometric study of surface BST2 ex-
pression revealed that compared to mock-infected hu-
mice, expression of the restriction factor was increased
on uninfected CD4+ T cells from WT or ΔVpu HIV-1
infected hu-mice (Figure 2C) very likely because of pro-
duction of human type I IFN in these mice as shown
below (Figure 2F). We also noticed an average of 15-20%
BST2 up regulation in infected T cells from HIV-1-
ΔVpu infected hu-mice and this was significant com-
pared to BST2 expression on uninfected T cells from the
same animals (Figure 2C-D) Importantly, surface BST2
expression was down regulated by 50-75% on p24+
splenic T cells from HIV-1-WT but not on those from
HIV-1-ΔVpu infected hu-mice (Figure 2C-D). Interest-
ingly, p24+ T cells from both groups of infected hu-mice
displayed comparable levels of cell-surface CD4 down
regulation relative to p24- T cells, consistent with the
remaining ability of both viruses to down regulate CD4
through Nef and Env (Figure 2C and 2E). Noticeably,
measurement of type I IFN levels in the plasma at differ-
ent time points revealed a marked difference between
WT and ΔVpu HIV-1 infected hu-mice at early time
points (8-wpi) (Figure 2F); however this difference be-
came non significant at later time points (16-wpi), sug-
gesting that the decreased difference in plasma viremia
observed over time between the two groups of mice is
not due to lower IFN production nor by extension to
lower BST2 levels. These findings indicate that Vpu is
critical for down regulating BST2 expression in vivo, and
that this effect most likely correlates with efficient initial
viral production and propagation in hu-mice infected
with low dose of HIV-1.
Effect of Vpu on the dynamic of viral infection at supra-
physiological dose of HIV-1
To investigate if exposing hu-mice to a supra-physiological
dose of infectious HIV-1-ΔVpu virus could overcome the
BST2 restriction on early HIV-1 expansion, we infected a
cohort of hu-mice with a 100-fold more virus (~500,000
TCID50 of HIV-1-WT or -ΔVpu virus). The infected
hu-mice were bled at 3, 7, 14 and 21-days post infection
(dpi). Hu-mice challenged with high dose of HIV-1-WT
or -ΔVpu showed detectable amounts of virus by 3-dpi.
However, compared to HIV-1-ΔVpu infected animals,
HIV-1-WT infected animals showed rapid increase in
plasma viremia at subsequent time points. In fact, by 14-
and 21-dpi there was an ~9- and ~15-fold increase, re-








































































































































































































































Figure 2 (See legend on next page.)
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Figure 2 Impact of Vpu-sufficiency and -deficiency on the dynamic of HIV-1 infection in hu-mice infected with low dose of virus.
(A) Kinetics of plasma viral load was measured by determining RNA copy numbers/ml (log10 values) in plasma at different time following
infection of hu-mice with low dose of HIV-1-WT or HIV-1-ΔVpu (n = 4 up to 10-wpi and n = 2 after 10-wpi for HIV-1-WT, and n = 4 for HIV-1-ΔVpu
at all time points); the horizontal broken line indicates the detection limit of the viral load assay (40 copies/ml). Viral load for mock-infected
animals was less than log10 value of 2. (B and C) T cells in spleen of low dose infected hu-mice were stained at 8 to 10-wpi with a combination
of antibodies to identify infected and uninfected CD4+ T cells. (B) Comparison of average frequency of p24+ T cells in spleen of hu-mice infected
with HIV-1-WT and HIV-1-ΔVpu (data pooled from 2 independent experiments; n≥ 5). (C) To determine the impact of Vpu on surface BST2 levels,
infected (p24+CD3+CD8-) or uninfected (p24-CD3+CD8-) T cells were gated (first column) and BST2 and CD4 expression was analyzed by two-
color dot plots (CD4 versus BST2 (second column) as well as by single color histograms (third and fourth columns). Numbers in the first column
represent frequency of p24+ T cells, and numbers in the upper and bottom left quadrants of dot plots represent BST2+CD4- and BST2-CD4-
frequency in p24+ T cells. (D) Comparison of relative levels of BST2 on uninfected (p24-) and infected (p24+) T cells from spleen of hu-mice
infected with the indicated HIV-1 virus (MFI on p24- T cells = 100%; n ≥ 5;). (E) Bar graph for relative CD4 down regulation on p24+ T cells from
hu-mice infected with the indicated HIV-1 virus relative to p24- cells (MFI on p24- T cells = 100%). (F) IFN levels were determined at 8-wpi and
16-wpi in plasma of hu-mice infected with WT or ΔVpu HIV-1 (for 8-wpi n = 4 for both groups and for 16-wpi n = 2 for WT and n = 4 for ΔVpu).
Error bars represent SD; *, p≤ 0.05; **, p = 0.002; ***, p≤ 0.0005. N.S.: not significant.
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fected animals (Figure 3A). In agreement with higher
plasma viral load, average frequency of p24+ T cells at 21-
dpi was ~ four-fold higher in spleen of hu-mice infected
with HIV-1-WT than those challenged with Vpu-deleted
HIV-1 (Figure 3B-C), and the infected T cells from HIV-1-
WT but not -ΔVpu challenged hu-mice showed significant
down regulation of BST2 (Figure 3C-D). That lower
plasma viral load in HIV-1-ΔVpu infected hu-mice was
largely due to impaired BST2 down regulation is sup-
ported by the fact that Vpu-deficient and proficient virus
down regulated CD4 (Figure 3C) or NTB-A (Figure 3C
and 3E) to a comparable extent. These data strongly sug-
gest that in the absence of Vpu, infection of hu-mice with
high dose of HIV-1 still fails to completely overcome BST2
restriction, thus highlighting the critical barrier that BST2
restriction might represent during acute infection in vivo.
Collectively, our results suggest that Vpu-mediated BST-2
antagonism is critical for HIV-1 replication and propaga-
tion in vivo, especially at early times post-infection.
Contribution of the E3 ubiquitin ligase recruiting domain
of Vpu in HIV-1 production and dissemination in hu-mice
While cell culture studies have provided important insight
into the mechanistic basis of Vpu-mediated BST2 an-
tagonism and HIV-1 release, it is not clear how Vpu
mutations that impair β-TrCP recruitment and inhibit
Vpu-mediated BST2 degradation affect HIV-1 infection
in vivo. To this end, we mutated the two CTD serine
residues at positions 52 and 56 for negatively charged
aspartic residues (HIV-1-VpuD52/56) in the context of the
pNL4.3-Ada-GFP proviral DNA (HIV-1-WT) since we
have previously shown that these substitutions prevented
the recruitment of β-TrCP and inhibited BST2 degradation
[16]. Transfection of HeLa cells with HIV-1-VpuD52/56
proviral DNA or infection of activated primary human
CD4+ T cells with HIV-1-VpuD52/56 revealed that the β-
TrCP-binding mutant was strongly attenuated in its ability
to promote HIV-1 particle release and down regulatesurface BST2, yet was able to down regulate CD4 at the
cell surface to levels comparable to Vpu-deficient or profi-
cient viruses. Noticeably, in the context of VpuAda, muta-
tion of the β-TrCP-interacting S52/56 motif did not
display residual BST2 antagonism in HeLa cells and
showed an impairment of virus production, which was
comparable to that of Vpu-defective virus in activated
CD4+ T cells (Figure 4).
To assess the effect of abrogating Vpu binding to β-
TrCP on BST2 antagonism and early HIV-1 propagation,
we infected hu-mice with high dose (~500,000 TCID50)
of HIV-1-WT, HIV-1-ΔVpu, or HIV-1-VpuD52/56. In-
fected mice were bled at 3, 7, 14, and 21-dpi. As de-
scribed above, infection of hu-mice with high dose of
HIV-1-WT but not HIV-1-ΔVpu resulted in high plasma
viremia; at 21-dpi HIV-1-WT infected animals showed ~
15-fold higher plasma viremia compared to HIV-1-ΔVpu
infected animals (Figure 5A-B). Interestingly, despite its
strongly attenuated BST2 antagonism phenotype in cell
culture assays, HIV-1-VpuD52/56 displayed a plasma vi-
remia that was intermediate between that in WT and
ΔVpu HIV infected hu-mice; at 21-dpi, ~three-fold less
HIV-1 viral particles (absolute values) were detected in
plasma of hu-mice infected with HIV-1-VpuD52/56 com-
pared to HIV-1-WT infected hu-mice (Figure 5B).
Analysis of the frequency of p24+ T cells in spleen of in-
fected hu-mice at 21-dpi showed that those infected with
HIV-1-ΔVpu contained about ~ five-fold less p24+ T cells
compared to those infected with HIV-1-WTas initially ob-
served (Figure 5C). Interestingly, the frequency of p24+
splenic T cells in HIV-1-VpuD52/56 infected hu-mice,
which also showed intermediate levels of plasma viremia,
was significantly lower and higher compared to HIV-
1-WT and HIV-1-ΔVpu infected animals, respectively
(Figure 5C). Further, type I IFN levels in peripheral blood
also showed a similar trend; highest and lowest amounts
of IFN were detected in plasma of HIV-1-WT or HIV-1-
ΔVpu infected hu-mice, respectively, whereas intermedi-
ate amounts of IFN were detected in plasma of hu-mice


























































































































































































































































































Figure 3 (See legend on next page.)
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Figure 3 Infection of hu-mice with supra physiological dose of HIV-1-ΔVpu does not overcome BST2 restriction on early viral
propagation. Hu-mice were infected with an inoculum containing 100-fold more (compared to low dose) infectious HIV-1-WT or HIV-1-ΔVpu
and bled at 3, 7, 14 and 21-dpi. (A) shows RNA copy number/ml of plasma (log10 values) at indicated time points in hu-mice infected with HIV-1-
WT or HIV-1 ΔVpu virus (n = 5). The horizontal broken line depicts the detection limit of the viral load assay as in the Figure 1. (B) Frequency of
p24+ T cells at 21-dpi in spleen of hu-mice infected with HIV-1-WT or HIV-1-ΔVpu (n≥ 4). (C) Impact of Vpu on BST2, CD4 and NTB-A levels on
p24- and p24+ T cells from individual hu-mouse infected with the indicated HIV-1 virus. (D) Comparison of relative BST2 levels on p24+ and p24-
T cells from spleen of hu-mice inoculated with the indicated HIV-1 virus at 21 dpi (MFI on p24- T cells = 100%; n≥ 4). (E) Bar graph for relative
NTB-A down regulation on p24+ T cells compared to p24- T cells from hu-mice infected with the indicated HIV-1 virus at 21dpi. Error bars
represent SD; *, p≤ 0.05; N.S.: not significant.
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the efficiency through which viral production and dissem-
ination was occurring (Figure 5A and C). These data sup-
port the notion that the β-TrCP recruiting motif of Vpu is
critical for optimal BST2 antagonism and for establishing
efficient viremia and propagation in vivo.
To investigate if graded levels of plasma viremia and
frequency of p24+ splenic T cells in hu-mice infected
with Vpu mutated virus was due to differential effects of
Vpu mutants on BST2 surface expression, we assessed
surface levels of the restriction factor on infected T cells.
As expected, compared to uninfected splenic T cells,
BST2 was down regulated by 50 to 65% on p24+ splenic
T cells from HIV-1-WT infected hu-mice, whereas as
described above it was up regulated (~20%) on p24+ T
cells from HIV-1-ΔVpu infected hu-mice (Figure 5E-F).
Compared to BST2 levels on p24- T cells, p24+ splenic T
cells from HIV-1-VpuD52/56 infected hu-mice showed
only an average of 20-30% BST2 down regulation. That
altered levels of BST2 at the cell surface correlated with
the extent of BST2 antagonism and viral propagation in
hu-mice infected with WT and Vpu mutant viruses is
supported by the fact that p24+ T cells from all infected
hu-mice, including those infected with Vpu mutant
virus, showed comparable down regulation of CD4
(Figure 5E-F). Collectively, these data suggest that Vpu-
mediated β-TrCP-dependent BST2 degradation contrib-
utes to efficient counteraction of BST2 restriction on
HIV-1 release and early viral dissemination in vivo by
ensuring that BST2 levels are efficiently reduced at the
surface of infected cells.
Discussion
The ability of Vpu to enhance HIV-1 release by counter-
acting the virus tethering function of BST2 has been
studied extensively in culture conditions. These studies
have provided important insights into the mechanisms
governing Vpu-mediated antagonism of BST2 and HIV-
1 release. In the present investigation we have attempted
to delineate the role of Vpu in HIV-1 production and
propagation during acute infection in vivo by infecting
hu-mice with low (5000 TCID50) or high (500,000
TCID50) dose of HIV-1 expressing or not Vpu. Our data
show that in condition of low dose of infection, Vpuprovides a crucial “jump” in establishing early plasma
viremia and HIV-1 propagation (Figure 2A). We also ob-
served higher frequency of p24+ T cells in spleen of hu-
mice infected with HIV-1-WT than with HIV-1-ΔVpu
(Figure 2B-C). Higher plasma viremia as well as fre-
quency of p24+ T cells in HIV-1-WT infected animals
appeared independent of Vpu effect on CD4 or NTB-A
expression as these two molecules were down regulated
to a similar extent on infected cells irrespective of the
presence or the absence of Vpu (Figures 2, 3 and 5).
Hence, as reported by Sato and colleagues [37], it ap-
pears that down regulation of NTB-A is not sufficiently
elicited by Vpu in vivo and the contribution of Vpu to
the overall CD4 down regulation remains minor as com-
pared to that of Nef and Env in this context. Our finding
that Vpu has a minor effect on CD4 downregulation
contrasts with the study of Sato and colleagues, which
indeed reported a down-regulation of CD4 by Vpu in
infected mice at 7 and 21 dpi, although Vpu-mediated
CD4 downregulation appeared less prominent at 21dpi
[37]. The reason for this discrepancy is not currently
understood. It may relate to the distinct Vpu variants
used in the two studies (ADA vs AD8), to the different
time points at which these analyses were performed (8-
10-wpi at low dose and 21dpi at high dose, in our study)
or to the efficiency of infection achieved in the two stud-
ies. While a very large proportion (between 80-95%) of
WT-HIV infected splenic CD4+ T cells expressed very
low amounts of surface CD4 in our hu-mice (Figures 2C
and 3C), Sato and colleagues detected significant CD4
expression at the cell surface of a sizeable number
(~74%) of WT HIV-1-infected cells at 7-dpi, despite ex-
pression of both Vpu and Nef.
In contrast to its negligible effect on CD4 surface ex-
pression, Vpu induced a very strong down regulation of
BST2; the presence of Vpu resulted in 50-75% BST2
down regulation on infected T cells, and interestingly,
lack of Vpu resulted in significant increase in BST2
levels on infected T cells compared to the uninfected
subset (Figure 2D). Similar to low dose infection, high
dose infection of hu-mice revealed a Vpu-dependent
down regulation of BST2 at the cell surface of infected
cells and an initial burst of viral replication and propaga-
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Figure 4 Characterization of HIV-1 proviral DNA encoding the Vpu S52/56 mutant. HeLa cells were transfected with HIV-1-WT, HIV-1-ΔVpu
or HIV-1-VpuD52/56 proviral DNA (pNL4.3-Ada-GFP backbone). Transfected cells and virus-containing supernatants were analyzed by Western blot
using the indicated antibodies (A). Relative viral particle efficiency. The particle release efficiency of HIV-1-WT was set at 100% (average of 3 inde-
pendent experiments) (B). Analysis of cell-surface BST2 expression by flow cytometry (C). Data are representative of 3 independent experiments.
PHA and IL-2 activated primary CD4+ T cells were infected with HIV-1-WT, HIV-1-ΔVpu, or HIV-1-VpuD52/56 virus at an MOI of 1. At different time
points post infection, cells were collected for flow cytometric analysis of CD4 and BST2 expression (D). Data is shown for cells collected at 3-dpi.
Relative BST2 and CD4 levels at 3-dpi on p24- (open bar) and p24+ (filled bar) cells are shown (MFI on p24-negative = 100%; n = 3). Infectious virus
production was determined in supernatants as described in Figure 1 (E). Data are representative of 3 independent experiments. Error bar represents
SD; * p≤ 0.05, ** p≤ 0.005, N.S.: not significant.
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at 21-dpi) was not as significant compared to those in-
fected with low dose at early time points (~150-fold at
4-wpi) (Figures 2 and 3). Together, these findings are
consistent with the notion that Vpu-mediated BST-2 an-
tagonism is critical for HIV-1 replication and propaga-
tion in vivo, especially at early times post-infection. They
further suggest that BST2 restriction represents a major
barrier during early infection when the predominant
mode of viral transmission is likely to occur through
cell-free virus. Hence, BST-2 antagonism by Vpu during
this critical phase would be required to ensure the effi-
cient initial viral expansion by cell-free virus necessary
for establishing infection, particularly in the face of a
host environment where a strong antiviral IFN response
is triggered early on [38]. Interestingly, the fact thatHIV-1 ΔVpu replication could reach levels similar to
those of HIV-1-WT at late time points post infection at
low dose suggests that over time BST2 antagonism by
Vpu appears less imperative most likely because viral
cell-to-cell transmission, a form of viral spread that is
highly efficient [39,40] and perhaps less sensitive to BST
2 restriction [9,41], becomes the predominant form of
viral propagation. Thus, the reduced difference in viral
outgrowth between WT and ΔVpu HIV-infected animals
at high dose despite similar effect on BST2 expression is
likely to result from the faster kinetic of cell-to cell
propagation that occurs under these supra physiological
conditions (Figure 3).
The BST2 antagonism phenotype displayed by the mu-
tant in the S52,56 motif of Vpu in cell culture assays was
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Figure 5 Effect of Vpu mutated in the β-TrCP-binding domain
on the dynamics of HIV infection in hu-mice. Hu-mice were
infected with high dose of HIV-1-WT, HIV-1-ΔVpu, or HIV-1-VpuD52/56
and plasma viral load was determined at different time points.
(A) shows kinetics of RNA copy number per ml of plasma (log10)
and (B) shows absolute values at 21-dpi in plasma of hu-mice
infected with the indicated HIV-1. Please note that x-axis crosses at
log10 value of 3.0. (C) shows comparison of the frequency of p24
+ T
cells in spleen of hu-mice infected with the indicated HIV-1 (n ≥ 7)
at 21-dpi. (D) shows type I IFN levels at 21-dpi in plasma of hu-mice
infected with the indicated HIV-1. (E) shows impact of Vpu mutations
on BST2 and CD4 levels on p24+ and p24- T cells from individual hu-
mouse infected with the indicated strain of HIV-1. (F) shows comparison
of relative BST2 and CD4 levels on p24+ (closed bar) and p24- (open bar)
T cells from spleen of hu-mice infected with the indicated strain of HIV-1
at 21-dpi (n≥ 4). BST2 and CD4 MFIs on p24-negative uninfected cells
were treated as 100%. Error bars represent SD; *, p≤ 0.05; **, p≤ 0.005,
***, p≤ 0.0005, N.S.: non significant.
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main unknown, but may involve higher expression levels
of BST2 in the cellular systems used in vitro, such that
weaker activities against BST2 are missed. Analysis of
the HIV-1-VpuD52/56 mutant suggests that the β-TrCP
recruiting determinants of Vpu contribute to efficient
counteraction of BST2 restriction on HIV-1 release and
early viral dissemination in vivo (Figure 5). The fact that
lack of β-TrCP interaction by Vpu is associated with a
complete impairment of Vpu-mediated CD4 degradation
further suggests that the residual initial jump of viremia
and dissemination displayed by this mutant is independ-
ent of Vpu-mediated CD4 down regulation. That BST2
down regulation is critical for HIV-1 propagation is fur-
ther supported by analysis of HIV-1-VpuD52/56 infected
hu-mice. These mice showed intermediate plasma vi-
remia and frequency of p24+ T cells compared to WT or
ΔVpu infected animals (Figure 5A-C) and these corre-
lated with a BST2 expression that was distinctly lower
on p24+ than p24- T cells (Figure 5E-F). Similarly, when
the BST2 phenotype of HIV-1-ΔVpu animals is taken
into consideration, down regulation seems to be almost
70 to 90% and 40-50% on p24+ T cells in WT or
VpuD52/56 infected animals, respectively, thus highlight-
ing the ability of this mutant to still interact with BST2
and retain a partial antagonism towards the restriction
factor [12,13,16]. At present, cause(s) of BST2 up regula-
tion by HIV-1 infection in the absence of Vpu is not
clear. It is possible that in vivo HIV-1 infection may up
regulate BST2 levels in IFN dependent and independent
manner and that the latter may reflect potential effects
of other HIV-1 proteins such as Nef, which has been
shown to up regulate BST2 levels on dendritic cells [42].
Alternatively, the upregulation of BST2 on T cells in-
fected with Vpu-defective virus may well be related to
“local” innate responses. Indeed, BST2 itself has been re-
ported to act as an innate sensor of HIV-1 assembly so
Dave et al. Retrovirology 2013, 10:128 Page 11 of 14
http://www.retrovirology.com/content/10/1/128that upon restriction of Vpu-defective HIV-1 release it
mediates signaling and induces NFκB-dependent proin-
flammatory gene expression [43]. Nevertheless, both
modes of BST2 up regulation (systemic vs local) appear
susceptible to Vpu-mediated antagonism.
Our data suggest that the BST2 restriction is providing
most of the growth retardation of the Vpu-defective and
S52,56 motif mutant since the contribution of Vpu to the
overall reduction of CD4 surface levels appears negligible.
However, we cannot completely exclude that the contribu-
tion of Vpu-mediated CD4 degradation to the early burst
of viral propagation may be masked by Nef. Indeed, it is
well known that Vpu and Nef effects on CD4 are taking
place at different time during infection and are spatially
separated in infected cells: Vpu promotes ER-associated
protein degradation (ERAD) of newly synthesized CD4
whereas Nef stimulates endocytosis of CD4 once it has
reached the plasma membrane [44]. Therefore, effects of
CD4 on envelope processing and particle infectivity are
also expected to be masked by Nef function, as the inhibi-
tory effect of CD4 on Env will occur before Nef can target
it. Analysis of the dynamic of infection of HIV-1 virus en-
coding Vpu mutants that are unable to target BST2, but
yet competent for CD4 degradation, should provide com-
plementary information about the contribution of Vpu-
mediated CD4 degradation to the establishment of early
HIV-1 expansion and propagation.
Lastly, our data also provide a plausible explanation
for the pandemic nature of HIV-1 group M but not N.
While Vpu of HIV-1 group M shows strongest BST2 an-
tagonism with contribution from its BST2-binding TMD
and β-TrCP-recruiting S52/56 motifs, some Vpu variants
of group N, like the VpuD52/56 mutant, are less efficient
at counteracting BST2 most likely because they are im-
paired in their ability to recruit β-TrCP and degrade the
mislocalized surface BST2 (as well as de novo synthe-
sized CD4) [45,46].
Conclusions
Our findings support the notion that optimal BST2 an-
tagonism by HIV-1 Vpu is critical for efficient early viral
expansion and dissemination during acute infection and




NOD-scid IL2Rγnull (NSG mice) were purchased from
Jackson laboratory and maintained under specific patho-
gen free conditions. Human cord blood was obtained
from the Cord Blood Research Bank, Sainte-Justine hos-
pital, Montreal, following approval of a research protocol
by the Sainte-Justine Hospital institutional review board
and written informed consent from donors. Cord blood-derived human CD34+ hematopoietic stem cells were iso-
lated by positive selection using human CD34+ selection
kit (Miltenyi Biotech). Purified cells were suspended at
a concentration of 1 × 106 cells per ml of complete RPMI
(10% fetal bovine serum (FBS), 100U/ml of penicillin/
streptomycin) and cultured for 4 hours in the presence of
recombinant human cytokines: Stromal Cell Factor (SCF,
50 ng/ml), Thrombopoietin (TPO, 25 ng/ml), Flt-3 ligand
(Flt-3 L, 50 ng/ml) and Interleukin-3 (IL-3, 10 ng/ml). All
cytokines were obtained from PeptroTech, USA. Cultured
stem cells were pelleted and suspended in Dulbecco’s
Phosphate Buffered Saline (PBS) (Invitrogen, Canada) at
1 × 106 stem cells per ml. Six to 7 week old NSG mice
were sub-lethally X-ray irradiated (250 rads) and 24 hours
later 1 × 105 stem cells were injected intravenously. More
than 90% of reconstituted mice showed the presence of hu-
man T cells in the blood 12 to 16 weeks post-engraftment.
Antibodies
CD14-PE-TR, CD4-PERCP CY5.5, CD45RA-PE-CY7,
CD45RO-APC, CD3-PB, CD8-APC-CY7, NTB-A-PE anti-
bodies were obtained from Biolegend. Anti-p24, PE or
FITC-coupled, were obtained from Beckman-Coulter. Goat
anti-rabbit Alexa633 was from Invitrogen. Anti-GFP was
from Sigma while anti-Vpu and anti-BST2 antibodies were
generated in the laboratory as previously described [16].
Cell culture
HEK 293 and 293 T cells, HeLa cells, HeLaTZM-bl cells
were maintained in complete DMEM as previously de-
scribed [47]. Primary CD4+ T cells were purified from
peripheral blood mononuclear cells (PBMCs) isolated
form healthy donors by negative selection kit (Stem Cell,
Canada) and suspended in complete RPMI at 1 × 106
cells/ml. CD4+ T cells were activated in the presence of
PHA (4 μg/ml) and IL-2 (100U/ml) for 24 hours, centri-
fuged (900 rpm), and suspended in complete RPMI/IL-2
[47]. PBMCs were obtained from healthy adult donors
who gave written informed consent in accordance with
the Declaration of Helsinki under research protocols
approved by the research ethics review board of the
Institut de Recherches Cliniques de Montréal (IRCM).
Construction of Vpu mutants
The infectious CCR5-tropic pNL4.3-Ada-GFP proviral
DNA (HIV-1 WT) was derived from a pNL4.3 construct
that co-expresses Nef and GFP (green fluorescent protein)
from an internal ribosome entry site-containing open read-
ing frame (ORF) (NL-GI) [48]. NL-GI was rendered CCR5-
tropic by transferring the SalI-BamHI fragment from a well
characterized CCR5-tropic construct Ada (NLHXADA) as
described previously [49]. The resulting pNL4.3-Ada-GFP
proviral construct, which encodes a Vpu protein from
ADA, was used for generating Vpu mutants using standard
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http://www.retrovirology.com/content/10/1/128molecular biology techniques. Vpu-deficient mutant (HIV-
1-ΔVpu) was generated by subcloning a SalI-KpnI frag-
ment from the Vpu-defective pNLVpuDEL-1 [50] into
pNL4.3-Ada-GFP. VpuDEL1 contains a deletion of 48 nu-
cleotides immediately following the initiator methionine
codon of the vpu ORF plus a 7-nucleotide insertion which
leads to a premature termination of the protein after 14
missense codons were introduced. The VpuD52/56 mutant
was generated as follows. In brief, 2.9 kb SalI-BamHI frag-
ment encompassing Vpu was subcloned into pSVCMV. In
this background, serine 52 and 56 residues in the CTD of
Vpu were mutated to aspartic acid (VpuD52/56) by Quick-
change mutagenesis (Stratagene). The mutated DNAs were
sequenced and cloned into the pNL4.3Ada-GFP backbone.Cell transfection, BST2 expression and virus release assay
Proviral DNAs expressing WT or mutated Vpu were
characterized by transfecting HeLa cells. In brief, 4 μg of
proviral DNA (pNL4.3-Ada-GFP-WT, pNL4.3-Ada-GFP-
ΔVpu, pNL4.3-Ada-GFP-VpuD52/56) was transfected into
HeLa cells using lipofectamine (Invitrogen). Forty-eight
hours later, cell free virus in culture supernatants was
pelleted and lysed in the presence of protease inhibitors
as described previously [16]. Cells were detached and an
aliquot was stained for BST2 and analyzed by flow cy-
tometry. Remainder of HeLa transfectants were lysed in
the presence of protease inhibitors. An aliquot of virus
and cell lysate was Western blotted for anti-p24, anti-
Vpu and anti-GFP. Relative release of virus was deter-
mined by comparing ratio of Gag (p24) band signal in
cell-free virus over total Gag-related band signals (virion-
associated plus cell-associated Gag-related bands) in
WT samples to Vpu-deleted or mutated samples (ratio in
WT was treated at 100%).Production of virus
5 × 106 293 T cells were plated in 100 mm tissue culture
plate and 24 hours later cells were transfected with
20 μg of proviral DNA by CaCl2 method. Culture super-
natants were collected 48 hours post-transfection and
virus was pelleted over a 20% sucrose cushion as de-
scribed [16] The pelleted virus was titrated using
HeLaTZM-bl indicator cell line for determining infec-
tious units. For determining tissue culture infectivity
dose (TCID50) total PBMC from healthy donors were ac-
tivated in the presence of PHA (4 μg/ml in complete
RPMI). Twenty four to 48 hours later, cells were washed,
counted and plated at 2 × 105 cells/well in a flat bottom
96-well plate and infected with serial dilution of purified
virus. At 7 days post infection, supernatant was collected
and p24 levels were estimated by anti-p24 ELISA and
TCID50 was calculated according to the Spearman-
Karber method.Primary CD4 T cell infection
Purified CD4+ T cells from healthy donors were PHA-
activated for 24 hours and 1 × 106 cells were infected
with Vpu-sufficient, deficient or Vpu-mutated HIV-1 at
an MOI of 1 in the presence of polybrene (8 μg/ml).
Four hours later, cells were washed twice and cultured
in complete RPMI containing IL-2 (100U/ml). At differ-
ent time points post infection, an aliquot of cells was re-
moved, stained for BST2 and CD4, and analyzed by flow
cytometry. Culture supernatant was collected, filtered
and release of cell-free virions was determined as fol-
lows. Two hundred microliters of supernatant was used
in duplicate for infecting 20,000 HeLaTZM-bl cells (in
24 well plates) for 2 hours in the presence of polybrene
and cultured in complete DMEM. At 48 hours post in-
fection, HeLaTZM-bl cells were washed twice with cold
PBS and lysed in luciferase buffer. Lysates were spun
(13,000 rpm for 10 min at 4°C) and luciferase units were
determined using the GlowMax assay (Promega).
Infection of hu-mice
NOD-scid IL2Rγnull (NSG) mice reconstituted with hu-
man CD34+ stem cells were infected intraperitoneally
with 5,000 or 500,000 TCID50 of HIV-1 in 200 μl of
complete RPMI. Medium was used for mock infection.
Mouse techniques
Hu-mice were bled at different time points post infec-
tion. Plasma was collected and PBMCs were purified
over Ficoll. Plasma was used for estimating HIV RNA
copy numbers (plotted as log10 values) and type I IFN
levels. PBMCs were then stained with a combination of
fluorescently labeled antibodies to CD14, CD4, CD45RA,
CD45RO, CD3, CD8 and BST2. For intracellular stain-
ing, surface stained cells were fixed and permeabilized
(Cytofix/Cytoperm kit from BD Biosciences) and stained
for HIV Gag protein. Infected hu-mice were sacrificed
by cardiac puncture and spleen was harvested. Red
blood cells in spleen were lysed using ACK buffer (Invi-
trogen) followed by surface and intracellular staining for
various proteins as described for PBMCs. Flow cytome-
try data were collected on a CYAN flow cytometer and
analyzed by Flowjo software. Mice were handled as per
Canadian Committee for Animal Care guidelines and
the protocol was approved by the IRCM animal care
committee.
Quantitation of HIV-1 RNA
HIV-1 viral load was determined in 100 μl of plasma. In
brief, 100 μl of plasma was diluted to 1 ml with normal
human serum and RNA copy numbers were determined
using the Abbott real time HIV-1 M2000 kit. The detec-
tion limit of the assay is 40 copies/ml.
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The assay to measure bioactive type 1 IFN levels was as
described previously [47] Briefly, 5 to 10 μl of plasma
obtained from hu-mice was mixed with 180 μl of human
type I IFN reporter HEK-Blue cells (Invivogen; 180,000
cells/ml), incubated for 24 to 48 hours, and an aliquot
of supernatant was mixed with Quantiblue (Cedarlane).
Change in optical density was measured at 650 nm using
a spectrophotometer. Type I IFN concentration (U/ml)
was extrapolated from the linear range of a standard
curve generated using known amounts of type I human
IFN (PBL Interferon Source).
Statistical analyses
Data are expressed as average with standard deviation
(SD). Statistical significance between different groups of
hu-mice was determined by unpaired student’s t test, while
statistical significance between subset of cells from the
same sample was determined by paired student’s t test (for
eg., BST2 levels on p24- versus p24+ T cells). *, **, and ***
signify p ≤ 0.05, p ≤ 0.005, and p ≤ 0.0005, respectively.
Additional file
Additional file 1: Figure S1. Hu-mice infected with low dose of HIV-1-
WT or HIV-1-ΔVpu were bled at different time points post infection.
Mononuclear cells were purified on Ficoll gradient and stained with a
combination of fluorescently-labeled antibodies. Frequency of p24+ T
cells (A) and CD4+ T cells (CD3+CD8-) (B) in peripheral blood lympho-
cytes (PBL) was determined by flow cytometry analysis. Error bars
represent SD; *, p ≤ 0.05.
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